Seqirus Begins Shipping 2017-2018 Influenza Vaccines

This article originally appeared here.
Share this content:
The Seqirus portfolio includes FLUAD® and FLUCELVAX QUADRIVALENT®.
The Seqirus portfolio includes FLUAD® and FLUCELVAX QUADRIVALENT®.

Seqirus announced it has begun shipping seasonal influenza vaccines for the upcoming 2017/18 flu season.

Seqirus will be offering both trivalent and quadrivalent formulations of the influenza vaccine, which were developed using egg- and cell-based technologies. In addition, Fluad (influenza vaccine, adjuvanted) will be available for patients aged ≥65 years, as well as Flucelvax Quadrivalent (influenza vaccine) for patients aged ≥4 years.

Specific vaccines in the Seqirus portfolio for the upcoming flu season include Afluria Quadrivalent (ages ≥18 years), the egg-based quadrivalent influenza vaccine, and Afluria (ages ≥5 years) and Fluvirin (ages ≥4 years), the egg-based trivalent influenza vaccines

Rapivab (peramivir injection) is also available as a 1-dose intravenous (IV) antiviral treatment for acute influenza in patients aged ≥18 years.

Seqirus vaccines are supplied as prefilled syringes as well as multi-dose vials. A needle-free injection option is also provided for Afluria and Afluria Quadrivalent.

Reference

Seqirus begins shipping 2017-2018 influenza vaccines to the U.S. market [news release]. Summit, NJ: Seqirus Inc. Published July 20, 2017; Accessed September 13, 2017.

You must be a registered member of Infectious Disease Advisor to post a comment.

Sign Up for Free e-newsletters